BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 596 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Holders of 5% or more of TECH
Holders whose latest Schedule 13D or 13G filing reports 5% or more of BIO-TECHNE Corp, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 13G/A | 7.20%11.4M shares | – | May 14, 20251 filing | May 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
1 Schedule 13D or 13G filing on BIO-TECHNE Corp, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20251:07 PM ET | Price T Rowe Associates Inc | 13G/A | 5.60%8.85M shares | −1.60 ppfrom 7.20% | Jun 30, 2025 | SEC |
| Jul 16, 20257:02 PM ET | BlackRock, Inc. | 13G/A | 7.00%11.0M shares | – | Jun 30, 2025 | SEC |
| May 14, 202510:45 AM ET | Price T Rowe Associates Inc | 13G/A | 7.20%11.4M shares | – | Mar 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell BIO-TECHNE Corp shares.
No Form 144 notices for BIO-TECHNE Corp are on file.